Zura Bio (NASDAQ:ZURA) Posts Earnings Results

Zura Bio (NASDAQ:ZURA) announced its earnings results on Thursday. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05), FiscalAI reports.

Zura Bio Trading Up 5.5%

Shares of ZURA opened at $4.79 on Friday. Zura Bio has a 1-year low of $0.98 and a 1-year high of $7.44. The stock has a market capitalization of $454.48 million, a P/E ratio of -4.39 and a beta of 0.09. The business’s 50-day moving average price is $5.94 and its 200 day moving average price is $5.16.

Insider Buying and Selling

In related news, major shareholder Ai Biotechnology Llc purchased 2,000,000 shares of the stock in a transaction dated Thursday, February 26th. The shares were acquired at an average cost of $6.25 per share, for a total transaction of $12,500,000.00. Following the acquisition, the insider directly owned 6,552,725 shares in the company, valued at approximately $40,954,531.25. The trade was a 43.93% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 14.23% of the company’s stock.

Institutional Investors Weigh In On Zura Bio

A number of large investors have recently bought and sold shares of ZURA. JPMorgan Chase & Co. boosted its position in Zura Bio by 78.7% during the second quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock worth $4,893,000 after purchasing an additional 2,052,732 shares during the period. Siren L.L.C. bought a new stake in Zura Bio during the fourth quarter worth approximately $6,812,000. VR Adviser LLC boosted its position in Zura Bio by 15.4% during the fourth quarter. VR Adviser LLC now owns 5,345,115 shares of the company’s stock worth $28,008,000 after purchasing an additional 713,899 shares during the period. Braidwell LP boosted its position in Zura Bio by 28.6% during the fourth quarter. Braidwell LP now owns 3,180,389 shares of the company’s stock worth $16,665,000 after purchasing an additional 707,583 shares during the period. Finally, Marshall Wace LLP boosted its position in Zura Bio by 228.5% during the fourth quarter. Marshall Wace LLP now owns 877,763 shares of the company’s stock worth $4,599,000 after purchasing an additional 610,563 shares during the period. 61.14% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Zura Bio in a research note on Wednesday, April 8th. Wedbush started coverage on Zura Bio in a research report on Monday, February 9th. They set an “outperform” rating and a $15.00 price target on the stock. Chardan Capital upped their price target on Zura Bio from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, March 23rd. Finally, Oppenheimer dropped their price target on Zura Bio from $16.00 to $15.00 and set an “outperform” rating on the stock in a research report on Friday, March 20th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.75.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.